Rosacea is a chronic inflammatory disease with complicated pathophysiology that involves genetic and environmental elements and dysregulation of innate and adaptive immunity, neurovascular responses, microbiome colonization or infection, resulting in recurrent inflammation. Rosacea has been reported associated with various gastrointestinal diseases including inflammatory bowel disease, celiac disease, irritable bowel syndrome, gastroesophageal reflux disease, Helicobacter pylori (HP) infection, and small intestine bacterial overgrowth (SIBO). The link may involve common predisposing genetic, microbiota, and immunological factors, comprising the theory of the gut–skin axis. Although the evidence is still controversial, interestingly, medications for eradicating SIBO and HP provided an effective and prolonged therapeutic response in rosacea, and conventional therapy for which is usually disappointing because of frequent relapses. In this article, we review the current evidence and discuss probable mechanisms of the association between rosacea and gastrointestinal comorbidities.
Conjunctivitis is commonly reported in dupilumab users with atopic dermatitis (AD), and few studies have compared the risk of conjunctivitis among patients with different indications. This study aimed to investigate the association between dupilumab and conjunctivitis in various diseases. The protocol of this study was registered on PROSPERO (ID CRD42023396204). The electronic search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov was conducted for the period from their inception to January 2023. Only placebo-controlled, randomized controlled trials (RCTs) were included. The main outcome was the incidence of conjunctivitis during the study period. The subgroup analysis was performed for patients with AD and non-AD indications, which include asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. In total, 23 RCTs involving 9153 patients were included for meta-analysis. Dupilumab users exhibited significantly higher risk of conjunctivitis (risk ratio [RR], 1.89; 95% confidence interval [CI], 1.34–2.67) than placebo users. Notably, significantly increased incidence of conjunctivitis was observed in the dupilumab group relative to the placebo group among patients with AD (RR, 2.43; 95% CI, 1.84–3.12) but not among patients with non-AD indications (RR, 0.71; 95% CI, 0.43–1.13). In conclusion, only dupilumab users with AD but not those with non-AD indications reported an elevated incidence of conjunctivitis.
17 January 2019 in International Journal of Dermatology
Cutaneous manifestations of Langerhans cell histiocytosis (LCH) are diverse and may mimic various dermatologic conditions, often leading to diagnostic challenges. We report a case of a 44-year-old woman who presented with multiple erythematous papules on the scalp, associated with tenderness and pruritus persisting for several months. Histopathological examination and immunohistochemical staining confirmed cutaneous LCH, consistent with her known systemic LCH involving the pituitary gland and sternum. An initial systemic chemotherapy protocol comprising weekly vinblastine and prednisolone, followed by an eight-week consolidation phase, failed to elicit a therapeutic response. Subsequent treatment with low-dose cytarabine (100 mg/m²), administered as a 5-day course every 28 days, also failed to achieve disease control. Local scalp radiotherapy yielded partial improvement but was limited by adverse effects. Due to chemoresistance and intolerance to radiotherapy, 5-aminolevulinic acid (5-ALA) based photodynamic therapy (PDT) was initiated. PDT led to marked clinical improvement of cutaneous lesions with minimal adverse effects. However, disease recurrence necessitated additional PDT sessions, which remained effective upon relapse. This case highlights the potential role of PDT as a safe and effective alternative for managing cutaneous LCH refractory to conventional therapies.